US 12,011,438 B2
Composition for protecting cardiomyocyte
Akira Kakizuka, Kyoto (JP); Koh Ono, Kyoto (JP); Takahiro Horie, Kyoto (JP); Yuya Ide, Kyoto (JP); Naritatsu Saitou, Kyoto (JP); and Takeshi Kimura, Kyoto (JP)
Assigned to KYOTO UNIVERSITY, Kyoto (JP)
Appl. No. 17/047,475
Filed by Kyoto University, Kyoto (JP)
PCT Filed Apr. 15, 2019, PCT No. PCT/JP2019/016083
§ 371(c)(1), (2) Date Oct. 14, 2020,
PCT Pub. No. WO2019/203176, PCT Pub. Date Oct. 24, 2019.
Claims priority of application No. 2018-078272 (JP), filed on Apr. 16, 2018.
Prior Publication US 2021/0145808 A1, May 20, 2021
Int. Cl. A61K 31/4418 (2006.01); A61K 9/00 (2006.01); A61P 9/10 (2006.01)
CPC A61K 31/4418 (2013.01) [A61K 9/0019 (2013.01); A61P 9/10 (2018.01)] 9 Claims
 
1. A method of protecting a cardiomyocyte in a subject in need thereof, the method comprising administering a therapeutically effective amount of a compound of formula (I):

OG Complex Work Unit Chemistry
wherein
Ra is selected from the group consisting of halo, hydroxy, alkyl, halo-substituted alkyl, aryl, halo- or alkyl-substituted aryl, alkoxy, hydroxy- or carboxy-substituted alkoxy, aryloxy, halo- or alkyl-substituted aryloxy, CHO, C(O)-alkyl, C(O)-aryl, C(O)-alkyl-carboxyl, C(O)-alkylene-carboxy ester, and cyano, and
m is an integer selected from 0 to 4,
or an ester, oxide, pharmaceutically acceptable salt or solvate thereof to the subject.